Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06955923 · ClinicalTrials.gov registry record · Phase 2
Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty
A Phase 2 study of Trigger Point Pain, Myofascial, sponsored by David Grant U.S. Air Force Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT06955923 is a Phase 2 study of Trigger Point Pain, Myofascial that has completed, run by David Grant U.S. Air Force Medical Center. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06955923, a Phase 2 study of Trigger Point Pain, Myofascial, has completed, sponsored by David Grant U.S. Air Force Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the ability of trigger point injections completed immediately following a total knee arthroplasty decrease pain scores and opioid use compared to sham injections. Given the current state of opioid dependency in the United States there needs to be a more focused attempt at treating post-operative pain without use of opioids. Given the manipulation of soft tissue during a total knee arthroplasty there seems to be a high correlation with pain and myofascial pain syndrome. This study will include an experimental (trigger point injection) and control (sham injection) group who are all undergoing a total knee arthroplasty. This is a pilot study that will include a maximum of 100 total patients (although it is planned for the study to be much smaller with a planned 10-15 patients per group). The procedure that will be completed is a trigger point injection with use of 1% lidocaine without epinephrine along the distal aspect of the vastus medialis and lateralis, proximal aspect of the medial and lateral gastrocnemius muscle bellies. The sham injection will be completed by pressing the needle against the skin without injecting any fluid. There will be a "blind" between the patient and the needle with both arms of the study. These patients will be followed up on POD1, and during weeks 2 and 6 follow-up where they will be given questionnaires to assess pain (visual analogue scale) and opioid use, and asked to bring their opioid medications to the clinic to assess the morphine milligrams equivalent (MME).
Conditions Studied
Interventions
- OTHER Sham Comparator
- DRUG Trigger point injection (lidocaine)
Study Locations (1)
California
- David Grant Medical Center - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2025-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06955923
The ClinicalTrials.gov registry entry for NCT06955923 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Grant U.S. Air Force Medical Center, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Trigger Point Pain, Myofascial appearing as the primary indexed condition, and to 2 interventions - of which Sham Comparator is the first listed.
NCT06955923 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06955923 about?
NCT06955923 is a clinical study titled "Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty". This study will evaluate the ability of trigger point injections completed immediately following a total knee arthroplasty decrease pain scores and opioid use compared to sham injections. Given the current state of opioid dependency in the United States there needs to be a more focused attempt at tr...
What is the current status of trial NCT06955923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2025-05-30. Estimated completion is 2025-08-26.
What conditions does trial NCT06955923 study?
This clinical trial studies the following conditions: Trigger Point Pain, Myofascial.
What interventions are being tested in trial NCT06955923?
The interventions under investigation include: Sham Comparator (OTHER), Trigger point injection (lidocaine) (DRUG).
Who is sponsoring clinical trial NCT06955923?
This trial is sponsored by David Grant U.S. Air Force Medical Center, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06955923 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trigger Point Pain, Myofascial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.